Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients
Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients
复制标题
DOI：
10.1002/ajh.23694
复制
发表时间：
2014-06-01
影响因子：
12.8
通讯作者：
Tefferi, Ayalew
中科院分区：
文献类型：
--
作者：
Barbui, Tiziano;Thiele, Juergen;Tefferi, Ayalew
对于未达到BCSH和WHO诊断标准所要求的红细胞压积(Hct)或血红蛋白(Hb)阈值的患者，建议诊断为真性遮盖性红细胞增多症(MPV)。对WHO严格定义的257例显性PV和140例MPV(根据BCSH定义为59 MPV)和397例原发性血小板增多症(ET)患者的Hct或Hb值与JAK2V617F、JAK2外显子12和CALR突变的表达进行了比较。MPV患者Hb、Hct阈值显著高于JAK2V617F ET(P
In patients not meeting the required hematocrit (HCT) or hemoglobin (Hb) thresholds according to BCSH and the WHO diagnostic criteria, the diagnosis of masked polycythemia vera (mPV) has been proposed. A comparison of HCT or Hb values with the expression of JAK2V617F, JAK2 exon 12, and CALR mutations in strictly WHO-defined 257 overt PV and 140 mPV (59 mPV according to BCSH) and 397 patients with essential thrombocythemia (ET) was performed. Hb and HCT thresholds of mPV patients were significantly higher than JAK2V617F ET (P